BG-12 in multiple sclerosis

Seminars in Neurology

Volumn 33, Issue 1, 2013, Pages 56-65

  Phillips, J Theodore ^a   Fox, Robert J ^b  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

BG 12; dimethyl fumarate; fumaric acids; multiple sclerosis; NF E2 related factor 2

Indexed keywords

ACETYLSALICYLIC ACID; BETA1 INTERFERON; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; GLATIRAMER; GLUTATHIONE TRANSFERASE M1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PEROXIREDOXIN 1; PLACEBO; STAT1 PROTEIN; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL PAIN; APOPTOSIS; ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; SKIN TOXICITY; TH1 CELL; VOMITING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION;

EID: 84878284582     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1343796     Document Type: Article

References (79)

1. Jacobs L. D., Cookfair D. L., Rudick R. A., et al. The Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol: 1996; 39 3 285 294 (Pubitemid 26100751)
2. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology: 1995; 45 7 1277 1285
3. PRISMS Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet: 1998; 352 9139 1498 1504
4. Johnson K. P., Brooks B. R., Cohen J. A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology: 1995; 45 7 1268 1276
5. Polman C. H., O'Connor P. W., Havrdova E., et al. AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 899 910
6. Rudick R. A., Stuart W. H., Calabresi P. A., et al. SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 911 923
7. Clifford D. B., De Luca A., Simpson D. M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol: 2010; 9 4 438 446
8. Kappos L., Radue E. W., O'Connor P., et al. FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med: 2010; 362 5 387 401
9. Cohen J. A., Barkhof F., Comi G., et al. TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med: 2010; 362 5 402 415
10. O'Connor P., Wolinsky J. S., Confavreux C., et al. TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med: 2011; 365 14 1293 1303
11. Genzyme Corp. Aubagio (Teriflunomide). Highlights of Prescribing Information. Available at: http://products.sanofi.us/aubagio/aubagio.pdf. Accessed September 14, 2012
12. Schweckendiek W. Heilung von Psoriasis vulgaris. [Treatment of psoriasis vulgaris]. Med Monatsschr: 1959; 13 2 103 104
13. Schweckendiek W. Behandlung von psoriasis mit lipoidloslichen fumarsaureverbindungen. Medizin Heute: 1966; 15 219 220
14. Schafer G. Fumarsaure lindert die schuppenflechte. Selecta: 1984; 15 1260 1261
15. Nugteren-Huying W. M., van der Schroeff J. G., Hermans J., Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol: 1990; 22 2 Pt 1 311 312 (Pubitemid 20209111)
16. Altmeyer P. J., Matthes U., Pawlak F., et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol: 1994; 30 6 977 981 (Pubitemid 24166567)
17. Hoefnagel J. J., Thio H. B., Willemze R., Bouwes Bavinck J. N. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol: 2003; 149 2 363 369 (Pubitemid 37100263)
18. Nieboer C., de Hoop D., Langendijk P. N., van Loenen A. C., Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica: 1990; 181 1 33 37 (Pubitemid 20207396)
19. Werdenberg D., Joshi R., Wolffram S., Merkle H. P., Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos: 2003; 24 6 259 273 (Pubitemid 37160613)
20. Litjens N. H., Burggraaf J., van Strijen E., et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol: 2004; 58 4 429 432 (Pubitemid 39312467)
21. Rostami-Yazdi M., Clement B., Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res: 2010; 302 7 531 538
22. Mrowietz U., Christophers E., Altmeyer P. The German Fumaric Acid Ester Consensus Conference Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol: 1999; 141 3 424 429 (Pubitemid 29448401)
23. Rostami-Yazdi M., Clement B., Schmidt T. J., Schinor D., Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol: 2009; 129 1 231 234
24. Schilling S., Goelz S., Linker R., Luehder F., Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol: 2006; 145 1 101 107 (Pubitemid 43893938)
25. Linker R. A., Lee D. H., Ryan S., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain: 2011; 134 Pt 3 678 692
26. Duffy S., So A., Murphy T. H. Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem: 1998; 71 1 69 77 (Pubitemid 28292536)
27. Scannevin R. H., Chollate S., Jung M. Y., et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther: 2012; 341 1 274 284
28. Lin S. X., Lisi L., Dello Russo C., et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro: 2011; 3 2
29. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol: 2004; 251 3 261 268 (Pubitemid 38387142)
30. Haider L., Fischer M. T., Frischer J. M., et al. Oxidative damage in multiple sclerosis lesions. Brain: 2011; 134 Pt 7 1914 1924
31. van Horssen J., Schreibelt G., Drexhage J., et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med: 2008; 45 12 1729 1737
32. Srinivasan R., Ratiney H., Hammond-Rosenbluth K. E., Pelletier D., Nelson S. J. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging: 2010; 28 2 163 170
33. van Horssen J., Drexhage J. A., Flor T., Gerritsen W., van der Valk P., de Vries H. E. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med: 2010; 49 8 1283 1289
34. Johnson D. A., Amirahmadi S., Ward C., Fabry Z., Johnson J. A. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci: 2010; 114 2 237 246
35. Moharregh-Khiabani D., Blank A., Skripuletz T., et al. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS ONE: 2010; 5 7 e11769
36. Ellrichmann G., Petrasch-Parwez E., Lee D. H., et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE: 2011; 6 1 e16172
37. Arnold H. M., Huang C., Huang R., et al. Neuroprotective effects of bg-12 on malonate-induced striatal lesion volume in Sprague-Dawley rat brain. Neurology: 2012; 78 01 P02121
38. Ghoreschi K., Mrowietz U., Röcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med (Berl): 2003; 81 8 471 480 (Pubitemid 37070199)
39. Frohman E. M., Racke M. K., Raine C. S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med: 2006; 354 9 942 955
40. Thio H. B., Zomerdijk T. P., Oudshoorn C., et al. Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Br J Dermatol: 1994; 131 6 856 861 (Pubitemid 24373965)
41. de Jong R., Bezemer A. C., Zomerdijk T. P., van de Pouw-Kraan T., Ottenhoff T. H., Nibbering P. H. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol: 1996; 26 9 2067 2074 (Pubitemid 26297503)
42. Asadullah K., Schmid H., Friedrich M., et al. Influence of monomethylfumarate on monocytic cytokine formation-explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res: 1997; 289 11 623 630 (Pubitemid 27510826)
43. Zoghi S., Amirghofran Z., Nikseresht A., Ashjazadeh N., Kamali-Sarvestani E., Rezaei N. Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients with fumaric acid esters. Immunol Invest: 2011; 40 6 581 596
44. Litjens N. H., Rademaker M., Ravensbergen B., Thio H. B., van Dissel J. T., Nibbering P. H. Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol: 2006; 154 2 211 217 (Pubitemid 43382688)
45. Vandermeeren M., Janssens S., Borgers M., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun: 1997; 234 1 19 23 (Pubitemid 27267523)
46. Zhu K. J., Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol: 2001; 116 2 203 208 (Pubitemid 32173722)
47. Litjens N. H., Rademaker M., Ravensbergen B., et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol: 2004; 34 2 565 575 (Pubitemid 39255966)
48. Peng H., Guerau-de-Arellano M., Mehta V. B., et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF- κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress activated kinase 1 (MSK1) signaling. J Biol Chem: 2012; 287 33 28017 28026
49. Ghoreschi K., Brück J., Kellerer C., et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med: 2011; 208 11 2291 2303
50. Treumer F., Zhu K., Gläser R., Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol: 2003; 121 6 1383 1388 (Pubitemid 38005490)
51. Schimrigk S., Brune N., Hellwig K., et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol: 2006; 13 6 604 610 (Pubitemid 43873632)
52. Fox R. J., Miller D. H., Phillips J. T., et al. CONFIRM Study Investigators Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med: 2012; 367 12 1087 1097
53. Gold R., Kappos L., Arnold D. L., et al. DEFINE Study Investigators Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med: 2012; 367 12 1098 1107
54. Talalay P., De Long M. J., Prochaska H. J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci U S A: 1988; 85 21 8261 8265
55. Friling R. S., Bensimon A., Tichauer Y., Daniel V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc Natl Acad Sci U S A: 1990; 87 16 6258 6262
56. Rushmore T. H., Pickett C. B. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J Biol Chem: 1990; 265 24 14648 14653
57. Itoh K., Mimura J., Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal: 2010; 13 11 1665 1678
58. Li W., Kong A. N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog: 2009; 48 2 91 104
59. Takaya K., Suzuki T., Motohashi H., et al. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med: 2012; 53 4 817 827
60. Brigelius-Flohé R., Flohé L. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal: 2011; 15 8 2335 2381
61. Schmidt T. J., Ak M., Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine-preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem: 2007; 15 1 333 342 (Pubitemid 44738571)
62. Lehmann J. CU, Listopad J. J., Rentzsch C. U., et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol: 2007; 127 4 835 845 (Pubitemid 46434667)
63. Schmidt M. M., Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int: 2010; 57 4 460 467
64. Thiessen A., Schmidt M. M., Dringen R. Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1. Neurosci Lett: 2010; 475 1 56 60
65. Gerdes S., Shakery K., Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol: 2007; 156 5 838 842 (Pubitemid 46642827)
66. Gesser B., Johansen C., Rasmussen M. K., et al. Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol: 2007; 127 9 2129 2137 (Pubitemid 47258496)
67. Bista P., Zeng W. K., Ryan S., Lukashev M., Yamamoto M. Dimethyl fumarate suppresses inflammation in vitro via both nrf2-dependent and nrf2-independent pathways. Neurology: 2012; 78 (Meeting Abstracts 1): P02.108
68. Hanson J., Gille A., Zwykiel S., et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest: 2010; 120 8 2910 2919
69. Sheikh S. I., Nestorov I., Russell H., et al. Safety, tolerability, and pharmacokinetics of bg-12 administered with and without aspirin: key findings from a randomized, double-blind, placebo-controlled trial in healthy volunteers [abstract]. Neurology: 2012; 78 (Meeting Abstracts 1): P04.136
70. Kappos L., Gold R., Miller D. H., et al. BG-12 Phase IIb Study Investigators Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet: 2008; 372 9648 1463 1472
71. Comi G., Filippi M., Wolinsky J. S. European/Canadian Glatiramer Acetate Study Group European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol: 2001; 49 3 290 297 (Pubitemid 32202781)
72. Gold R., Miller D. H., Phillips J. T., et al. Clinical efficacy of BG-12 in relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Paper presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon, France
73. Miller D., Gold R., Fox R. J., et al. Effects of BG-12 on magnetic resonance imaging outcomes in relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 define and confirm studies Paper presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon, France
74. Sormani M. P., Bonzano L., Roccatagliata L., Cutter G. R., Mancardi G. L., Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol: 2009; 65 3 268 275
75. Mikol D. D., Barkhof F., Chang P., et al. REGARD study group Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol: 2008; 7 10 903 914
76. Cadavid D., Wolansky L. J., Skurnick J., et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology: 2009; 72 23 1976 1983
77. O'Connor P., Arnason B., Comi G., et al. Interferon beta-1b 500 mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® efficacy yielding outcomes of a new dose study. Neurology: 2008; 70 11 LBS.004
78. Calabresi P., Radue E. W., Goodin D., et al. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): Results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study). Neurology: 2012; 79 e90 e91
79. Kappos L., Comi G., Confavreux C., et al. The efficacy and safety of teriflunomide in patients with relapsing MS: Results from TOWER, a phase III, placebo-controlled study (abstract) Abstract presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 9-13, 2012; Lyon, France